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Severe Aortic Stenosis in Dialysis Patients
Yuichi Kawase, MD; Tomohiko Taniguchi, MD; Takeshi Morimoto, MD, MPH; Kazushige Kadota, MD; Keiichiro Iwasaki, MD;
Akimune Kuwayama, MD; Masanobu Ohya, MD; Takenobu Shimada, MD; Hidewo Amano, MD; Takeshi Maruo, MD; Yasushi Fuku, MD;
Chisato Izumi, MD; Takeshi Kitai, MD; Naritatsu Saito, MD; Eri Minamino-Muta, MD; Takao Kato, MD; Tsukasa Inada, MD;
Moriaki Inoko, MD; Katsuhisa Ishii, MD; Tatsuhiko Komiya, MD; Michiya Hanyu, MD; Kenji Minatoya, MD; Takeshi Kimura, MD; on behalf of
the CURRENT AS Registry Investigators*
Background-—Characteristics and prognosis of hemodialysis patients with severe aortic stenosis have not yet been well defined.
Methods and Results-—The CURRENT AS (contemporary outcomes after surgery and medical treatment in patients with severe
aortic stenosis) registry, a Japanese multicenter registry, enrolled 3815 consecutive patients with severe aortic stenosis. There
were 405 hemodialysis patients (initial aortic valve replacement [AVR] group: N=135 [33.3%], and conservative group: N=270) and
3410 nonhemodialysis patients (initial AVR group: N=1062 [31.1%], and conservative group: N=2348). The median follow-up
duration after the index echocardiography was 1361 days, with 90% follow-up rate at 2 years. The cumulative 5-year incidence of
all-cause death was significantly higher in hemodialysis patients than in nonhemodialysis patients in both the entire cohort (71%
versus 40%, P<0.001) and in the initial AVR group (63.2% versus 17.9%, P<0.001). Among hemodialysis patients, the initial AVR
group as compared with the conservative group was associated with significantly lower cumulative 5-year incidences of all-cause
death (60.6% versus 75.5%, P<0.001) and sudden death (10.2% versus 31.7%, P<0.001). Nevertheless, the rate of aortic valve
procedure–related death, which predominantly occurred within 6 months of the AVR procedure, was markedly higher in the
hemodialysis patients than in the nonhemodialysis patients (21.2% and 2.3%, P<0.001).
Conclusions-—Among hemodialysis patients with severe aortic stenosis, the initial AVR strategy as compared with the conservative
strategy was associated with significantly lower long-term mortality risk, particularly the risk for sudden death, although the effect
size for the survival benefit of the initial AVR strategy was smaller than that in the nonhemodialysis patients. ( J Am Heart Assoc.
2017;6:e004961. DOI: 10.1161/JAHA.116.004961.)
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T he number of patients with end-stage renal diseaserequiring hemodialysis has been gradually increasing. In
2012, more than 400 000 American patients with end-stage
renal disease were on hemodialysis, including over 98 000
new patients.1 In Japan, more than 300 000 patients with
end-stage renal disease are on hemodialysis, and the
candidate pool increases by over 30 000 patients per year.2
Dialysis patients are associated with a higher risk for the
development of cardiovascular diseases with calcified degen-
eration of cardiac valves and/or heavy calcification of
coronary arteries.3–6 Calcified aortic stenosis (AS) is partic-
ularly common in hemodialysis patients, and has been found
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to be an independent risk factor for death in hemodialysis
patients.6,7 Regarding the clinical outcomes of hemodialysis
patients with severe AS, there are only a few small studies
suggesting the higher mortality and morbidity rates following
surgical aortic valve replacement (AVR).8–10 However, the
characteristics and prognosis of hemodialysis patients with
severe AS have not yet been well defined in comparison with
those in nonhemodialysis patients with severe AS. Also, it is
not clear whether the effect size of the initial AVR strategy
relative to the conservative strategy differs between
hemodialysis patients and nonhemodialysis patients, although
we previously reported that the initial AVR strategy was
associated with markedly lower mortality risk than the
conservative strategy in the asymptomatic patients with
severe AS.11 Therefore, we sought to investigate the long-
term outcomes of hemodialysis patients with severe AS and
to evaluate the effect of the initial AVR strategy relative to the
conservative strategy in clinical outcomes compared between
hemodialysis and nonhemodialysis patients in a large
Japanese observational database of consecutive patients with
severe AS.
Methods
Study Design and Patient Population
The study design of the CURRENT AS (contemporary outcomes
after surgery and medical treatment in patients with severe
aortic stenosis) registry was previously described in detail.11 In
brief, the CURRENT AS registry is a retrospective, multicenter
registry that enrolled 3815 consecutive patients with severe AS
from 27 centers (Appendix S1, on-site surgical facility in 20
centers) in Japan between January 2003 and December 2011.
We examined the hospital database of transthoracic echocar-
diography and enrolled consecutive patients meeting the
definition of severe AS (peak aortic jet velocity >4.0 m/s,
mean aortic pressure gradient >40 mm Hg, or aortic valve area
<1.0 cm2) for the first time during the study period. We
excluded patients with a history of aortic valve repair/
replacement/plasty or percutaneous aortic balloon valvulo-
plasty. The institutional review boards in all 27 participating
centers approved the protocol. Written informed consent from
each patient was waived because clinical information was
obtained from the routine practice, and no patient refused to
participate in the study when contacted for follow-up.
Among the 3815 study patients, there were 405 hemodial-
ysis patients (initial AVR group: N=135 [33.3%], and conser-
vative group: N=270) and 3410 nonhemodialysis patients
(initial AVR group: N=1062 [31.1%], and conservative group:
N=2348) at the time of the index echocardiography (Fig-
ure 1). The conservative group consisted of all the patients
other than those in whom AVR was planned based on the
index echocardiographic findings. The conservative
Study population
3815 consecutive patients with severe AS













Figure 1. Study flow chart. AS indicates aortic stenosis; AVR, aortic valve replacement.
Clinical Perspective
What Is New?
• Although the initial aortic valve replacement strategy
improves prognosis of hemodialysis patients with severe
aortic stenosis, the magnitude of its benefit is smaller in
hemodialysis patients than in nonhemodialysis patients,
which could at least in part be explained by the extremely
high rate of aortic valve procedure–related death in
hemodialysis patients.
What Are the Clinical Implications?
• The initial aortic valve replacement is an effective procedure
to treat hemodialysis patients with severe aortic stenosis,
but there is an urgent unmet need to improve the procedural
outcomes of aortic valve replacement in hemodialysis
patients.
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management included watchful waiting for symptoms in
asymptomatic patients, and medical management of angina
and/or heart failure in symptomatic patients. There were 3
main reasons why AVR was not performed in the conservative
group. First, patients were considered to have no formal AVR
indications by their attending physician (1388 patients,
53.0%) either because of absence of symptoms (1067
patients) or improvement of symptoms by medication (237
patients). Second, patients had unacceptably high surgical
risk (798 patients, 30.5%). Third, patients refused to undergo
AVR (403 patients, 15.4%).
The effect of the initial AVR strategy relative to the
conservative strategy was assessed based on the initial
strategies regardless of the actual performance of AVR. The
follow-up was commenced on the day of the index echocar-
diography except for the analysis comparing the clinical
outcomes after AVR between hemodialysis and nonhemodial-
ysis patients, in which the follow-up was commenced on the
day of AVR.
Echocardiography
All patients underwent a comprehensive 2-dimensional and
Doppler echocardiographic evaluation in each participating
center. Peak aortic jet velocity and mean pressure gradient
were obtained with the use of the simplified Bernoulli
equation. Aortic valve area was calculated with the use of
the standard continuity equation and was indexed by body
surface area.12
Data Collections and Definitions
Baseline clinical information was collected by reviewing the
hospital charts or database. Follow-up information was
collected mainly by reviewing the hospital charts, and
additional information was collected through contact with
patients, their families, and/or referring physicians by sending
mails regarding survival status, symptoms, and subsequent
hospitalizations.
The primary outcome measure in the present analysis was
all-cause death. The secondary outcome measures included
cardiovascular death, aortic valve–related death, aortic valve
procedure–related death, sudden death, noncardiovascular
death, hospitalization for heart failure (HF), and a composite of
aortic valve–related death or hospitalization for HF. The causes
of death were classified according to the Valve Academic
Research Consortium definitions and were adjudicated by a
clinical event committee (Data S1).13,14 Aortic valve–related
death included aortic valve procedure–related death, sudden
death, and death attributable to HF possibly related to the aortic
valve. Hospitalization for HF was defined as hospitalization
because of worsening HF requiring intravenous drug therapy.
Statistical Analysis
Categorical variables are presented as numbers and percent-
ages and were compared with the v2 test or Fisher exact test.
Continuous variables are presented as the mean and SD or
median and interquartile range. Continuous variables were
compared using Student t test or Wilcoxon rank sum test
based on their distributions. The Kaplan–Meier method was
used to calculate the cumulative incidence of events, and the
differences were assessed with the log-rank test.
The Cox proportional hazard models were used to estimate
the adjusted risk of hemodialysis patients relative to non-
hemodialysis patients or the adjusted risk of initial AVR strategy
relative to conservative strategy for all-cause death, cardiovas-
cular death, aortic valve–related death, aortic valve procedure–
related death, sudden death, noncardiovascular death,
hospitalization for HF, and a composite of aortic valve–related
death and hospitalization for HF. We selected 20 clinically
relevant factors listed in Table 1 and Tables S1 and S2 as the
risk-adjusting variables consistent with the previous report. We
constructed parsimonious models with a limited number of
variables for aortic valve procedure–related death, because the
number of patients with this event was too small for the
nonparsimonious model. We selected 6 clinically relevant
variables as the risk-adjusted variables as listed in Table 1 and
Tables S1 and S2 in the parsimoniousmodels. The centers were
incorporated into all the models as the stratification variable.
With the exception of age, the continuous variables were
dichotomized by the median values or clinically meaningful
reference values. Because the differences in the age distribu-
tions between the hemodialysis and nonhemodialysis groups
and between the initial AVR and conservative strategies were
too large to allow the dichotomous approach, we treated age as
a continuous variable in the Cox proportional hazard models.
The risks for the clinical end points were expressed as hazard
ratios and their 95% CI. We also evaluated the interaction
between hemodialysis/nonhemodialysis subgroups and the
effect of the initial AVR strategy relative to the conservative
strategy for the primary and secondary outcome measures.
All statistical analyses were conducted by 2 physicians (Y.K.
and T.T.) and a statistician (T.M.) with the use of JMP 10.0.2 or
SAS 9.4. All reported P values were 2-tailed, and P<0.05 was
considered statistically significant.
Results
Baseline Characteristics and Clinical Outcomes:
Hemodialysis Versus Nonhemodialysis Patients
Baseline characteristics were significantly different between
hemodialysis patients and nonhemodialysis patients
(Table 1).
DOI: 10.1161/JAHA.116.004961 Journal of the American Heart Association 3
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Patients (N=3410) P Value
Age, y 73.28.6 78.39.7 <0.001
Age ≥80 y*† 93 (23) 1636 (48) <0.001
Men* 242 (60) 1201 (35) <0.001
Body mass index‡ 20.53.6 21.93.8 <0.001
Body mass index <22* 298 (74) 2028 (59) <0.001
Body surface area, m2 1.460.18 1.460.19 0.47
Initial treatment strategies 0.37
Initial AVR strategy* 135 (33) 1062 (31)
Conservative strategy* 270 (67) 2348 (69)
Any symptoms possibly related to aortic stenosis 198 (49) 1807 (53) 0.12
Angina 60 (15) 438 (13) 0.27
Syncope 25 (6) 173 (5) 0.34
Heart failure 143 (35) 1460 (43) 0.004
Admission for heart failure at index echocardiography*† 60 (15) 730 (21) 0.002
Hypertension* 287 (71) 2380 (70) 0.66
Current smoking* 22 (5) 174 (5) 0.78
History of smoking 120 (30) 710 (21) <0.001
Dyslipidemia 78 (19) 1249 (37) <0.001
On statin therapy 45 (11) 925 (27) <0.001
Diabetes mellitus 127 (31) 770 (23) <0.001
On insulin therapy* 36 (9) 152 (4) <0.001
Prior myocardial infarction* 48 (12) 275 (8) 0.01
Prior percutaneous coronary intervention 97 (24) 405 (12) <0.001
Prior coronary artery bypass grafting 45 (11) 154 (5) <0.001
Prior open heart surgery 51 (13) 265 (8) <0.001
Prior symptomatic stroke* 70 (17) 433 (13) 0.01
Atrial fibrillation or flutter*† 100 (25) 728 (21) 0.12
Aortic/peripheral vascular disease* 82 (20) 200 (6) <0.001
Serum creatinine, mg/dL 0.83 (0.68–1.1)
Years from dialysis introduction
<1 y 33 (8)
≥1 y, <5 y 116 (29)
≥5 y, <10 y 87 (21)
≥10 y 169 (42)
Anemia*§ 335 (83) 1782 (52) <0.001
Liver cirrhosis (Child-Pugh B or C)* 6 (1) 32 (1) 0.29
Malignancy 59 (15) 458 (13) 0.53
Malignancy currently under treatment*† 13 (3) 136 (4) 0.44
Chest wall irradiation 2 (0.5) 23 (1) 1.0
Immunosuppressive therapy 17 (4) 114 (3) 0.37
Continued
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Patients (N=3410) P Value
Chronic lung disease 40 (10) 360 (11) 0.67
Chronic lung disease
(moderate or severe)*
11 (3) 101 (3) 0.78
Coronary artery disease* 195 (48) 949 (28) <0.001
Logistic EuroSCORE, % 13.4 (7.9–23.0) 9.4 (5.5–16.1) <0.001
EuroSCORE II, % 2.7 (1.9–4.6) 2.9 (1.6–4.9) 0.10
STS-PROM score, % 8.5 (5.6–12.3) 3.5 (2.1–5.7) <0.001
Etiology of aortic stenosis <0.001
Degenerative 394 (97) 2985 (88)
Congenital (unicuspid, bicuspid,
quadricuspid)
4 (1) 254 (7)
Rheumatic 5 (1) 145 (4)
Infective endocarditis 1 (0.3) 6 (0.2)
Others 1 (0.3) 20 (0.6)
Echocardiographic variables
Left ventricular end-diastolic diameter, mm 48.97.2 45.66.9 <0.001
Left ventricular end-systolic diameter, mm 34.28.8 29.87.7 <0.001
Left ventricular ejection fraction, % 56.914.0 63.513.3 <0.001
Left ventricular ejection fraction <40% 57 (14) 236 (7) <0.001




Posterior wall thickness in diastole, mm 11.42.0 10.92.0 <0.001
Peak aortic jet velocity, m/s 3.960.87 4.160.92 <0.001
Peak aortic jet velocity ≥5 m/s 52 (13) 646 (19) 0.003
Peak aortic jet velocity ≥4 m/s*† 211 (52) 1974 (58) 0.03
Peak aortic pressure gradient, mm Hg 6628 7232 <0.001
Mean aortic pressure gradient, mm Hg 3717 4120 <0.001
Aortic valve area (equation
of continuity), cm2
0.740.17 0.720.19 0.03
Aortic valve area index, cm2/m2 0.510.12 0.500.13 0.18
Any combined valvular disease
(moderate or severe)*†
166 (41) 1392 (41) 0.95
Moderate or severe aortic regurgitation 77 (19) 714 (21) 0.37
Moderate or severe mitral stenosis 14 (3) 119 (3) 0.97
Moderate or severe mitral regurgitation 102 (25) 661 (19) 0.006
Moderate or severe tricuspid regurgitation 64 (16) 564 (17) 0.71
Tricuspid regurgitation pressure
gradient ≥40 mm Hg*
80 (20) 526 (15) 0.02
Values are number (%), meanSD, or median (interquartile range) unless otherwise stated. AVR indicates aortic valve replacement; PROM, predicted risk of mortality; STS, Society of
Thoracic Surgeons.
*Potential independent variables selected in the Cox proportional hazard models for all-cause death, cardiovascular death, aortic valve–related death, sudden death, noncardiovascular
death, hospitalization for heart failure, and a composite of aortic valve–related death or hospitalization for heart failure.
†Potential independent variables selected in the Cox proportional hazard models for aortic valve procedure–related death.
‡Body mass index was calculated as weight in kilograms divided by height in meters squared.
§Anemia was defined by the World Health Organization criteria (hemoglobin <12.0 g/dL in women and <13.0 g/dL in men).
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The median follow-up period after the index echocardiog-
raphy was 1361 (interquartile range: 1055–1697) days, with a
90% follow-up rate at 2 years. Cumulative 5-year incidence of
the first surgical AVR or transcatheter aortic valve implanta-
tion (TAVI) was significantly higher in hemodialysis patients
than in nonhemodialysis patients in the entire study popula-
tion as well as in the conservatively managed population
(Figure 2 and Figure S1). TAVI was performed in 40 patients
including 1 hemodialysis patient during the follow-up period.
Cumulative 5-year incidence of the primary outcome
measure (all-cause death) was significantly higher in
hemodialysis patients than in nonhemodialysis patients (71%
versus 40%, P<0.001) with a notably higher rate in the first
year (35.9% versus 13.4%) after the index echocardiography
(Table 2 and Figure 3). The risk for sudden death was
markedly higher in hemodialysis patients than in non-
hemodialysis patients (Table 2 and Figure 3). Cumulative
5-year incidence of hospitalization for HF was not significantly
different between hemodialysis and nonhemodialysis patients
(Table 3). The results from the adjusted analysis were fully
consistent with those from the unadjusted analysis (Table 3).
Baseline Characteristics and Clinical Outcomes in
Hemodialysis and Nonhemodialysis Patients:
Initial AVR Versus Conservative Strategies
The differences in baseline characteristics between the initial
AVR and conservative groups were basically consistent in
both hemodialysis and nonhemodialysis patients. Surgical risk
scores were significantly lower in the initial AVR group than in
the conservative group. Patients in the initial AVR group had
greater echocardiographic AS severity and left ventricular wall
thickness than those in the conservative group (Table 3,
Table S1).
In both hemodialysis and nonhemodialysis patients, cumu-
lative 5-year incidence of all-cause death was significantly
lower in the initial AVR group than in the conservative group
(Table 4 and Figure 4). However, the effect size of the initial
Interval 0 d 30 d 1 y 3 y 5 y
Dialysis
N of patients with surgical AVR or TAVI 69 149 177 181
N of patients at risk 405 310 141 41 6
Cumulative incidence 17.7% 41.5% 56.8% 64.9%
Non-dialysis
N of patients with surgical AVR or TAVI 442 1171 1428 1534
N of patients at risk 3410 2845 1741 900 210
Cumulative incidence 13.3% 36.5% 47.7% 57.4%

























Figure 2. Cumulative incidence of surgical AVR or TAVI: dialysis vs nondialysis patients. Follow-up was
commenced on the day of the index echocardiography. AVR indicates aortic valve replacement; TAVI,
transcatheter aortic valve implantation.
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 http://ahajournals.org by on August 6, 2020
AVR strategy relative to the conservative strategy on mortality
was smaller in hemodialysis patients than in nonhemodialysis
patients (adjusted hazard ratio 0.62, 95% CI 0.43–0.90,
P=0.01, and adjusted hazard ratio 0.40, 95% CI 0.33–0.48,
P<0.001, P interaction=0.001) (Table 4). In both hemodialysis
and nonhemodialysis patients, the lower risks of the initial
AVR group relative to the conservative group were highly
significant for sudden death and HF hospitalization (Table 4
and Figure 4). In addition, we have conducted a propensity-
score matched analysis as a sensitivity analysis and analyzed
the initial AVR versus conservative groups in hemodialysis and
nonhemodialysis patients, respectively. The results of
Table 2. Clinical Outcomes: Dialysis VS Nondialysis Patients
Dialysis Patients Nondialysis Patients
Unadjusted HR (95% CI) P Value Adjusted HR (95% CI) P Value
Number of Patients








All-cause death 248 (71.0) 1201 (40.0) 2.69 (2.34–3.08) <0.001 2.76 (2.35–3.25) <0.001
Cardiovascular death 183 (59.5) 769 (27.8) 3.07 (2.60–3.60) <0.001 3.18 (2.62–3.86) <0.001
Aortic valve–related death 107 (36.1) 502 (19.2) 2.69 (2.17–3.31) <0.001 3.10 (2.41–3.98) <0.001
Aortic valve procedure–related death 32 (9.9) 49 (1.9) 7.02 (4.44–10.93) <0.001 6.74 (4.17–10.91) <0.001
Sudden death 52 (24.7) 144 (5.7) 4.70 (3.38–6.43) <0.001 4.80 (3.23–7.14) <0.001
Noncardiovascular death 65 (28.5) 432 (16.9) 2.00 (1.52–2.57) <0.001 2.05 (1.52–2.77) <0.001
Hospitalization for heart failure 57 (31.9) 755 (29.2) 0.96 (0.72–1.24) 0.76 0.84 (0.63–1.13) 0.26
A composite of aortic valve–related
death or hospitalization for heart failure
136 (51.6) 936 (34.1) 1.78 (1.48–2.12) <0.001 1.63 (1.33–2.00) <0.001
Number of patients with at least 1 event was counted through the entire follow-up period, while the cumulative incidence was truncated at 5 years. Follow-up was commenced on the day
of the index echocardiography. HR indicates hazard ratio.
All-cause death
Interval 0 d 30 d 1 y 3 y 5 y
Dialysis
N of patients with event 22 139 217 240
N of patients at risk 405 377 239 117 24
Cumulative incidence 5.5% 35.9% 58.3% 71.0%
Non-dialysis
N of patients with event 81 445 880 1088
N of patients at risk 3410 3271 2815 1854 580















































Interval 0 d 30 d 1 y 3 y 5 y
Dialysis
N of patients with event 6 30 47 52
N of patients at risk 405 377 239 117 24
Cumulative incidence 1.5% 9.3% 17.3% 24.7%
Non-dialysis
N of patients with event 9 56 101 125
N of patients at risk 3410 3271 2815 1854 580




Figure 3. Cumulative incidence of all-cause death and sudden death: dialysis vs nondialysis patients. Follow-up was commenced on the day of
the index echocardiography.
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Table 3. Baseline Characteristics in Dialysis and Nondialysis Patients: Initial AVR VS Conservative Groups
Variables








Group (N=2348) P Value
Age, y 70.38.2 74.78.4 <0.001 73.78.9 80.39.4 <0.001
Age ≥80 y*† 17 (13) 76 (28) <0.001 282 (27) 1354 (58) <0.001
Men* 87 (64) 155 (57) 0.17 420 (40) 781 (33) <0.001
Body mass index‡ 20.83.1 20.33.9 0.24 22.53.6 21.73.9 <0.001
Body mass index <22* 95 (70) 203 (75) 0.30 527 (50) 1501 (64) <0.001
Any symptoms possibly related to aortic stenosis 103 (76) 95 (35) <0.001 802 (76) 1005 (43) <0.001
Angina 33 (24) 27 (10) <0.001 258 (24) 180 (8) <0.001
Syncope 15 (11) 10 (4) 0.007 95 (9) 78 (3) <0.001
Heart failure 72 (53) 71 (26) <0.001 587 (55) 873 (37) <0.001
Admission for heart failure at index echocardiography*† 28 (21) 32 (12) 0.02 242 (23) 488 (21) 0.19
Hypertension* 97 (72) 190 (70) 0.76 710 (67) 1670 (71) 0.01
Current smoking* 12 (9) 10 (4) 0.03 71 (7) 103 (4) 0.005
Diabetes mellitus on insulin therapy* 11 (8) 25 (9) 0.71 47 (4) 105 (4) 0.95
Prior myocardial infarction* 11 (8) 37 (14) 0.10 40 (4) 235 (10) <0.001
Prior open heart surgery 12 (9) 39 (14) 0.11 36 (3) 229 (10) <0.001
Prior symptomatic stroke* 19 (14) 51 (19) 0.23 88 (8) 345 (15) <0.001
Atrial fibrillation or flutter*† 29 (21) 71 (26) 0.29 178 (17) 550 (23) <0.001
Aortic/peripheral vascular disease* 12 (9) 70 (26) <0.001 58 (5) 142 (6) 0.50
Years from dialysis introduction 0.21
<1 y 8 (6) 25 (9)
≥1 y, <5 y 33 (24) 83 (31)
≥5 y, <10 y 29 (21) 58 (21)
≥10 y 65 (48) 104 (39)
Anemia*§ 121 (90) 214 (79) 0.009 508 (48) 1274 (54) <0.001
Liver cirrhosis (Child-Pugh B or C)* 2 (1) 4 (1) 1.0 4 (0.4) 28 (1) 0.02
Malignancy currently under treatment*† 2 (1) 11 (4) 0.23 22 (2) 114 (5) <0.001
Chronic lung disease (moderate or severe)* 5 (4) 6 (2) 0.52 14 (1) 87 (4) <0.001
Coronary artery disease* 76 (56) 119 (44) 0.02 322 (30) 627 (27) 0.03
STS-PROM score, % 7.3 (4.8–11.4) 8.9 (5.9–13.0) 0.007 2.5 (1.6–4.1) 3.9 (2.4–6.7) <0.001
Echocardiographic variables
Left ventricular ejection fraction, %* 58.113.2 56.414.4 0.25 63.414.0 63.512.9 0.72
Left ventricular ejection fraction <50% 32 (24) 73 (27) 0.47 173 (16) 315 (13) 0.03
Peak aortic jet velocity, m/s 4.410.82 3.740.80 <0.001 4.740.82 3.890.84 <0.001
Peak aortic jet velocity ≥4 m/s*† 100 (74) 111 (41) <0.001 894 (84) 1080 (46) <0.001
Mean aortic pressure gradient, mm Hg 4918 3215 <0.001 5420 3617 <0.001
Aortic valve area (equation of continuity), cm2 0.690.16 0.760.16 <0.001 0.640.17 0.750.18 <0.001
Any combined valvular disease (moderate or severe)*† 65 (48) 101 (37) 0.04 414 (39) 978 (42) 0.14
Tricuspid regurgitation pressure gradient ≥40 mm Hg* 32 (24) 48 (18) 0.16 148 (14) 378 (16) 0.11
Values are number (%), meanSD, or median (interquartile range) unless otherwise stated. AVR indicates aortic valve replacement; PROM, predicted risk of mortality; STS, Society of
Thoracic Surgeons.
*Potential independent variables selected in the Cox proportional hazard models for all-cause death, cardiovascular death, and a composite of aortic valve–related death or hospitalization
for heart failure.
†Potential independent variables selected in the Cox proportional hazard models for aortic valve–related death, aortic valve–procedure death, sudden death, noncardiovascular death, and
hospitalization for heart failure.
‡Body mass index was calculated as weight in kilograms divided by height in meters squared.
§Anemia was defined by the World Health Organization criteria (hemoglobin <12.0 g/dL in women and <13.0 g/dL in men).
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sensitivity analysis were similar to those of the primary
analysis (Tables S3 through S6 and Figures S2 and S3).
Baseline Characteristics and Clinical Outcomes
After AVR: Hemodialysis Versus Nonhemodialysis
Patients
Among the 135 hemodialysis and 1062 nonhemodialysis
patients in the initial AVR group, surgical AVR or TAVI was
actually performed in 131 patients (97%) and 1043 patients
(98%), respectively. TAVI was performed only in 11 non-
hemodialysis patients. The differences in baseline clinical and
echocardiographic characteristics between hemodialysis and
nonhemodialysis patients in the initial AVR group were
consistent with those in the entire study population
(Table S2). The procedural characteristics in 1174 patients
who actually underwent AVR based on the initial treatment
strategy are presented in Table S3. Hemodialysis patients
Table 4. Clinical Outcomes in Dialysis and Nondialysis Patients: Initial AVR VS Conservative Groups
Initial AVR Group Conservative Group
Unadjusted
HR (95% CI) P Value
Adjusted
HR (95% CI) P Value P Interaction
Number of Patients













Dialysis patients 66 (60.6) 182 (75.5) 0.61 (0.46–0.81) <0.001 0.62 (0.43–0.90) 0.01
Nondialysis patients 170 (18.7) 1031 (49.3) 0.30 (0.25–0.35) <0.001 0.40 (0.33–0.48) <0.001
Cardiovascular death 0.004
Dialysis patients 48 (48.6) 135 (64.5) 0.61 (0.43–0.84) 0.002 0.64 (0.41–0.98) 0.04
Nondialysis patients 103 (11.3) 666 (35.6) 0.28 (0.23–0.35) <0.001 0.36 (0.28–0.45) <0.001
Aortic valve–related death <0.001
Dialysis patients 27 (21.8) 80 (44.6) 0.60 (0.38–0.91) 0.02 0.57 (0.34–0.94) 0.03




Dialysis patients 26 (21.2) 6 (3.4) 8.19 (3.60–22.00) <0.001 7.99 (2.91–21.93) <0.001
Nondialysis patients 24 (2.3) 25 (1.8) 1.87 (1.07–3.28) 0.03 1.43 (0.75–2.73) 0.28
Sudden death 0.06
Dialysis patients 4 (10.2) 48 (31.7) 0.14 (0.04–0.35) <0.001 0.15 (0.05–0.44) <0.001
Nondialysis patients 23 (3.0) 121 (7.2) 0.35 (0.22–0.54) <0.001 0.38 (0.23–0.62) <0.001
Noncardiovascular death 0.11
Dialysis patients 18 (23.4) 47 (30.9) 0.64 (0.36–1.09) 0.10 0.73 (0.37–1.45) 0.37
Nondialysis patients 67 (8.3) 365 (21.3) 0.33 (0.26–0.43) <0.001 0.50 (0.37–0.67) <0.001
Hospitalization for heart failure 0.66
Dialysis patients 10 (26.9) 47 (31.7) 0.32 (0.15–0.61) <0.001 0.16 (0.06–0.42) <0.001
Nondialysis patients 92 (10.5) 663 (38.7) 0.23 (0.19–0.29) <0.001 0.24 (0.19–0.31) <0.001
A composite of aortic
valve–related
death or hospitalization
because of heart failure
0.01
Dialysis patients 36 (42.2) 100 (56.1) 0.59 (0.40–0.85) 0.005 0.62 (0.38–1.02) 0.06
Nondialysis patients 129 (13.9) 807 (44.0) 0.27 (0.23–0.33) <0.001 0.27 (0.22–0.33) <0.001
Number of patients with at least 1 event was counted through the entire follow-up period, while the cumulative incidence was truncated at 5 years. Follow-up was commenced on the day
of the index echocardiography. AVR indicates aortic valve replacement; HR, hazard ratio.
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Interval 0 d 30 d 1 y 3 y 5 y
Initial AVR group
N of patients with event 4 36 51 61
N of patients at risk 135 132 85 49 12
Cumulative incidence 3.0% 28.1% 41.9% 60.6%
Conservative group
N of patients with event 18 103 166 179
N of patients at risk 270 245 154 68 12






































Interval 0 d 30 d 1 y 3 y 5 y
Initial AVR group
N of patients with event 7 60 118 148
N of patients at risk 1062 1048 960 672 236
Cumulative incidence 0.7% 5.8% 11.8% 18.7%
Conservative group
N of patients with event 74 385 762 940
N of patients at risk 2348 2223 1855 1182 344
Cumulative incidence 3.2% 16.9% 34.6% 49.3%
Years after diagnosis
Non-dialysis patients

























Interval 0 d 30 d 1 y 3 y 5 y
Initial AVR group
N of patients with event 1 2 3 4
N of patients at risk 135 132 85 49 12
Cumulative incidence 0.7% 1.5% 2.7% 10.2%
Conservative group
N of patients with event 5 28 44 48
N of patients at risk 270 245 154 68 12
Cumulative incidence 1.9% 13.1% 24.8% 31.7%
Years after diagnosis
Non-dialysis patients























Interval 0 d 30 d 1 y 3 y 5 y
Initial AVR group
N of patients with event 2 10 15 19
N of patients at risk 1062 1048 960 672 236
Cumulative incidence 0.2% 1.0% 1.6% 3.0%
Conservative group
N of patients with event 7 46 86 106
N of patients at risk 2348 2223 1855 1182 344
Cumulative incidence 0.3% 2.2% 4.6% 7.2%
Years after diagnosis












Figure 4. Cumulative incidence of all-cause death (A) and sudden death (B) in dialysis patients and nondialysis patients:
initial AVR vs conservative strategies. Follow-up was commenced on the day of the index echocardiography. AVR indicates
aortic valve replacement.
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more often underwent AVR combined with coronary artery
bypass grafting and less often AVR combined with replace-
ment of ascending aorta than nonhemodialysis patients. A
bioprosthetic valve was less often used in hemodialysis
patients than in nonhemodialysis patients (Table S7).
Hemodialysis patients were associated with markedly higher
risk for all-cause death and aortic valve procedure–related
death after AVR than nonhemodialysis patients (Table 5,
Figure 5). The 30-day mortality rate after AVR was 7.6% in
hemodialysis patients, which was markedly higher than 1.3%
in nonhemodialysis patients (Figure 5). The rate of aortic
valve procedure–related death, which predominantly occurred
within 6 months of the AVR procedure, was markedly higher in
the hemodialysis patients than in the nonhemodialysis
patients (21.2% and 2.3%, P<0.001) (Table 5 and Figure 5).
In hemodialysis patients, the cumulative 5-year incidences of
all-cause death and hospitalization for HF were not signifi-
cantly different between the bioprosthetic and mechanical
valves (Figure S4). Only 2 patients underwent redo AVR in the
80 hemodialysis patients who received the bioprosthetic
valve.
Discussion
The main findings of the present study are as follows: (1)
Hemodialysis patients with severe AS have a significantly
poorer prognosis than nonhemodialysis patients with severe
AS; (2) The initial AVR strategy as compared with the
conservative strategy in hemodialysis patients was associated
with significantly lower long-term mortality risk, particularly
the risk for sudden death; (3) However, the AVR procedure-
related mortality was much higher in hemodialysis patients
than that in nonhemodialysis patients.
Previous small studies have suggested the poor prognosis
after AVR in hemodialysis patients with severe AS.6–10 The
present study including a large number of hemodialysis
patients with severe AS clearly demonstrated that hemodial-
ysis patients had a significantly higher 5-year cumulative
mortality rate than nonhemodialysis patients (71% versus
40%) with a notably higher rate in the first year (35.9% versus
13.4%), although AVR was more often performed in hemodial-
ysis patients than in nonhemodialysis patients. Compared
with the survival rates of 89.7% at 1 year and 60.5% at 5 years
after hemodialysis introduction reported from the Society for
Dialysis Therapy, the mortality rate of our study is consider-
ably higher, suggesting the grimmer prognosis of hemodial-
ysis patients with severe AS, although the durations after the
hemodialysis introduction were variable in the present study.2
Furthermore, the rate of sudden death in hemodialysis
patients was remarkably high (9.3% at 1 year and 24.7% at
5 years) in the present study. The 5-year rate of sudden death
was much higher than 10.5% at 4 years after percutaneous
coronary intervention reported in Japanese hemodialysis
patients.15
AVR is the only definitive treatment in patients with severe
AS. In the present study, the initial AVR strategy as compared
with the conservative strategy was associated with a signif-
icantly lower long-term mortality rate in hemodialysis patients
as well as in nonhemodialysis patients. A dramatically lower
risk for sudden death in the initial AVR group would have been
one of the major contributors for the lower long-term
mortality in hemodialysis patients with severe AS. Further-
more, markedly lower risk for HF hospitalization in the initial
Table 5. Clinical Outcomes After AVR: Dialysis VS Nondialysis Patients
Dialysis Patients Nondialysis Patients
Unadjusted
HR (95% CI) P Value
Adjusted
HR (95% CI) P Value
Number of Patients








All-cause death 64 (63.2) 156 (17.9) 5.19 (3.84–6.93) <0.001 4.00 (2.75–5.81) <0.001
Cardiovascular death 47 (52.6) 92 (10.7) 6.24 (4.34–8.86) <0.001 5.30 (3.32–8.48) <0.001
Aortic valve–related death 26 (21.2) 30 (3.0) 8.22 (4.82–13.94) <0.001 9.31 (5.20–16.68) <0.001
Aortic valve procedure–related death 26 (21.2) 24 (2.3) 10.12 (5.78–17.78) <0.001 10.86 (5.87–20.07) <0.001
Noncardiovascular death 17 (22.4) 64 (8.0) 3.57 (2.02–5.99) <0.001 4.87 (2.69–8.82) <0.001
Hospitalization for heart failure 9 (25.6) 84 (9.8) 1.43 (0.67–2.70) 0.33 1.65 (0.80–3.40) 0.18
A composite of aortic valve–related
death or hospitalization for heart failure
34 (40.8) 112 (12.3) 3.63 (2.43–5.28) <0.001 2.90 (1.80–4.66) <0.001
Number of patients with at least 1 event was counted through the entire follow-up period, while the cumulative incidence was truncated at 5 years. Follow-up was commenced on the day
of surgical AVR or TAVI. AVR indicates aortic valve replacement; HR, hazard ratio; TAVI, transcatheter aortic valve implantation.
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AVR strategy might also have contributed to the lower long-
term mortality in hemodialysis patients with severe AS. On
the other hand, it should be noted that the long-term mortality
rate of hemodialysis patients with severe AS is very high even
after AVR as compared with that in nonhemodialysis patients.
Thourani et al reported the 5-year mortality rate of 71.5%
after AVR in 114 hemodialysis patients, which was compa-
rable to 63.2% in 131 hemodialysis patients in the present
study.8 The effect size of the initial AVR strategy relative to
the conservative strategy for all-cause death was smaller in
hemodialysis patients than in nonhemodialysis patients,
which could be explained by the extremely high rate of aortic
valve procedure–related death in hemodialysis patients,
predominantly occurring within 6 months of the AVR proce-
dure. The major causes of aortic valve procedure–related
death were infection and hemorrhage. When undergoing
surgical AVR, hemodialysis patients are more likely to have an
increased risk of perioperative infection and hemorrhage
because of having higher preoperative morbidity, more
concomitant diseases, and more severe atherosclerosis than
nonhemodialysis patients, which may have increased postop-
erative mortality rates in hemodialysis patients. Therefore,
reduction in the procedural mortality of AVR is essential to
improve the overall mortality outcome of hemodialysis
patients with severe AS. In this context, less invasive TAVI
might be an attractive alternative to surgical AVR in
hemodialysis patients with severe AS. Currently, there are
only a few small studies reporting outcomes of TAVI in
hemodialysis patients; reported 30-day mortality rates
included 14.0% (6/43) (transfemoral: 6.5%, and nontrans-
femoral: 33.3%) by Szerlip et al, 15.2% (5/33) by Dumonteil
et al, and 0% (0/17) by Maeda et al.16–18 Further investiga-
tion on the role of TAVI in hemodialysis patients with severe
AS is urgently needed.
Study Limitations
The present study has several limitations. First, its observa-
tional study design was prone to inherent bias. Particularly,
the comparison between the initial AVR and conservative
strategies would have been influenced by selection bias
toward choosing less morbid patients in the initial AVR
strategy. Also, the conservative group is a heterogeneous
population and includes those with indications for surgery
who were thought to be too risky and those not meeting
indications for AVR because they were without symptoms.
This could be noted as the Society of Thoracic Surgeons
predicted risk of mortality is higher in the conservative group,
yet the mean aortic pressure gradient is lower in this group.
Despite an extensive multivariable adjustment, we could not
All-cause death
Interval 0 d 30 d 1 y 3 y 5 y
Dialysis
N of patients with event 10 35 50 60
N of patients at risk 131 120 83 44 10
Cumulative incidence 7.6% 27.9% 42.1% 63.2%
Non-dialysis
N of patients with event 13 54 106 135
N of patients at risk 1043 1013 945 629 227
Cumulative incidence 1.3% 5.3% 10.9% 17.9%
























Aortic valve procedure-related death







Interval 0 d 30 d 1 y 3 y 5 y
Dialysis
N of patients with event 10 25 26 26
N of patients at risk 131 120 83 44 10
Cumulative incidence 7.6% 20.1% 21.2% 21.2%
Non-dialysis
N of patients with event 13 21 23 23
N of patients at risk 1043 1013 945 629 227

















Years after surgical AVR/TAVI
Figure 5. Cumulative incidence of all-cause death and aortic valve procedure–related death after surgical AVR/TAVI in the initial AVR group:
dialysis vs nondialysis patients. In the initial AVR group, 1174 of 1197 patients actually underwent surgical AVR or TAVI. Follow-up was
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deny the possibility of unmeasured confounders and selection
bias. Also, we did not take the competing risk of death into
account for the nonfatal outcomes and also the competing
risks of various causes of death. Secondly, we did not
evaluate the influence of the duration after introduction of
hemodialysis on long-term outcomes. Thirdly, the threshold to
choose the AVR strategy and procedural outcomes of AVR
might be different across the participating centers in this
multicenter registry. Finally, the number of patients undergo-
ing TAVI in our study was too small to clarify prognosis of
hemodialysis patients undergoing TAVI.
Conclusions
Among hemodialysis patients with severe AS, the initial AVR
strategy as compared with the conservative strategy was
associated with significantly lower long-term mortality risk,
particularly the risk for sudden death, although the effect size
for the survival benefit of the initial AVR strategy was smaller
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Definitions of the clinical events 
Death was regarded as having its origin in cardiovascular unless obvious non-
cardiovascular causes were identified. Sudden death was defined as unexplained death of 
stable patients. Any death during hospitalization for aortic valve replacement or 
transcatheter aortic valve implantation was regarded as aortic valve procedure-related 
death. Aortic valve-related death included aortic valve procedure death, sudden death, 
and death due to heart failure related to aortic stenosis. Heart failure hospitalization was 
defined as hospitalization due to worsening heart failure requiring intravenous drug 
therapy. Myocardial infarction during the follow-up period was defined in accordance 
with the universal myocardial infarction guidelines.1 Stroke was defined as ischemic or 
hemorrhagic stroke either requiring or prolonging hospitalization with symptoms lasting 
>24 hours. Life-threatening/disabling or major bleeding was defined as Bleeding 
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Table S1. Baseline Characteristics of Dialysis and Non-dialysis Patients: Initial AVR versus Conservative Groups   
Variables Dialysis patients Non-dialysis patients 













Age, years 70.3±8.2 74.7±8.4 <0.001 73.7±8.9 80.3±9.4 <0.001 
  Age ≥80 years*† 17 (13) 76 (28) <0.001 282 (27) 1354 (58) <0.001 
Men* 87 (64) 155 (57) 0.17 420 (40) 781 (33) <0.001 
Body mass index‡ 20.8±3.1 20.3±3.9 0.24 22.5±3.6 21.7±3.9 <0.001 
  Body mass index <22* 95 (70) 203 (75) 0.30 527 (50) 1501 (64) <0.001 
Body surface area, m2 1.49±0.18 1.45±0.17 0.04 1.50±0.18 1.43±0.19 <0.001 
Any symptoms possibly related to aortic stenosis 103 (76) 95 (35) <0.001 802 (76) 1005 (43) <0.001 
Angina 33 (24) 27 (10) <0.001 258 (24) 180 (8) <0.001 
Syncope 15 (11) 10 (4) 0.007 95 (9) 78 (3) <0.001 
Heart failure 72 (53) 71 (26) <0.001 587 (55) 873 (37) <0.001 
Admission for heart failure at index echocardiography*† 28 (21) 32 (12) 0.02 242 (23) 488 (21) 0.19 
Hypertension* 97 (72) 190 (70) 0.76 710 (67) 1670 (71) 0.01 
Current smoking* 12 (9) 10 (4) 0.03 71 (7) 103 (4) 0.005 
History of smoking 51 (38) 69 (26) 0.01 263 (25) 447 (19) <0.001 
Dyslipidemia 23 (17) 55 (20) 0.42 453 (43) 796 (34) <0.001 
On statin therapy 13 (10) 32 (12) 0.50 326 (31) 599 (26) 0.002 
Diabetes mellitus 32 (24) 95 (35) 0.02 244 (23) 526 (22) 0.71 
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Prior myocardial infarction* 11 (8) 37 (14) 0.10 40 (4) 235 (10) <0.001 
Prior percutaneous coronary intervention 26 (19) 71 (26) 0.12 77 (7) 328 (14) <0.001 
Prior coronary artery bypass graft 10 (7) 35 (13) 0.09 22 (2) 132 (6) <0.001 
Prior open heart surgery 12 (9) 39 (14) 0.11 36 (3) 229 (10) <0.001 
Prior symptomatic stroke* 19 (14) 51(19) 0.23 88 (8) 345 (15) <0.001 
Atrial fibrillation or flutter*† 29 (21) 71 (26) 0.29 178 (17) 550 (23) <0.001 
Aortic/peripheral vascular disease* 12 (9) 70 (26) <0.001 58 (5) 142 (6) 0.50 
Years from dialysis introduction 0.21 
< 1 year 8 (6) 25 (9) 
  ≥ 1 year, < 5 years 33 (24) 83 (31) 
  ≥ 5 year, < 10 years 29 (21) 58 (21) 
  ≥ 10 years 65 (48) 104 (39) 
Anemia§* 121 (90) 214 (79) 0.009 508 (48) 1274 (54) <0.001 
Liver cirrhosis (Child-Pugh B or C)* 2 (1) 4 (1) 1.0 4 (0.4) 28 (1) 0.02 
Malignancy 15 (11) 44 (16) 0.16 116 (11) 342 (15) 0.004 
  Malignancy currently under treatment*† 2 (1) 11 (4) 0.23 22 (2) 114 (5) <0.001 
Chest wall irradiation 1 (1) 1 (0.4) 1.0 6 (0.6) 17 (0.7) 0.60 
Immunosuppressive therapy 9 (7) 8 (3) 0.08 22 (2) 92 (4) 0.006 
Chronic lung disease 19 (14) 21 (8) 0.045 122 (11) 238 (10) 0.23 
  Chronic lung disease (moderate or severe)* 5 (4) 6 (2) 0.52 14 (1) 87 (4) <0.001 
Coronary artery disease* 76 (56) 119 (44) 0.02 322 (30) 627 (27) 0.03 
Logistic EuroSCORE, % 11.3 (7.1-18.9) 15.9 (8.8-25.1) <0.001 6.6 (4.2-10.6) 10.8 (6.6-18.3) <0.001 
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STS-PROM score, % 7.3 (4.8-11.4) 8.9 (5.9-13.0) 0.007 2.5 (1.6-4.1) 3.9 (2.4-6.7) <0.001 
Etiology of aortic stenosis 0.05 <0.001 
  Degenerative 130 (96) 264 (98) 844 (79) 2141 (91) 
  Congenital (Unicuspid, Bicuspid, Quadricuspid) 0 4 (1) 154 (15) 100 (4) 
  Rheumatic 4 (3) 1 (0.4) 49 (5) 96 (4) 
  Infective endocarditis 1 (1) 0 5 (0.5) 1 (0.04) 
  Others 0 1 (0.4) 10 (1) 10 (0.4) 
Echocardiographic variables 
Left ventricular end-diastolic diameter, mm 49.6±7.0 48.6±7.4 0.20 46.9±7.1 45.0±6.7 <0.001 
Left ventricular end-systolic diameter, mm  34.6±8.5 34.1±9.0 0.60 30.6±8.4 29.4±7.2 <0.001 
Left ventricular ejection fraction, %* 58.1±13.2 56.4±14.4 0.25 63.4±14.0 63.5±12.9 0.72 
  Left ventricular ejection fraction <40% 16 (12) 41 (15) 0.36 87 (8) 149 (6) 0.049 
  Left ventricular ejection fraction <50% 32 (24) 73 (27) 0.47 173 (16) 315 (13) 0.03 
Interventricular septum thickness in diastole, mm 12.4±2.6 11.4±2.2 <0.001 11.9±2.3 11.0±2.2 <0.001 
Posterior wall thickness in diastole, mm 12.1±2.2 11.0±1.8 <0.001 11.5±2.1 10.6±1.9 <0.001 
Peak aortic jet velocity, m/s 4.41±0.82 3.74±0.80 <0.001 4.74±0.82 3.89±0.84 <0.001 
Peak aortic jet velocity ≥5m/s 33 (24) 19 (7) <0.001 396 (37) 250 (11) <0.001 
Peak aortic jet velocity ≥4m/s*† 100 (74) 111 (41) <0.001 894 (84) 1080 (46) <0.001 
Peak aortic pressure gradient, mmHg 80±29 59±25 <0.001 93±32 63±28 <0.001 
Mean aortic pressure gradient, mmHg 49±18 32±15 <0.001 54±20 36±17 <0.001 
Aortic valve area (equation of continuity), cm2 0.69±0.16 0.76±0.16 <0.001 0.64±0.17 0.75±0.18 <0.001 
Aortic valve area index, cm2/m2 0.46±0.10 0.53±0.12 <0.001 0.43±0.12 0.53±0.13 <0.001 
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Moderate or severe aortic regurgitation 35 (26) 42 (16) 0.01 259 (24) 455 (19) 0.001 
Moderate or severe mitral stenosis 8 (6) 6 (2) 0.08 43 (4) 76 (3) 0.23 
Moderate or severe mitral regurgitation 39 (29) 63 (23) 0.22 188 (18) 473 (20) 0.09 
Moderate or severe tricuspid regurgitation 21 (16) 43 (16) 0.92 126 (12) 438 (19) <0.001 
Tricuspid regurgitation pressure gradient ≥40 mmHg* 32 (24) 48 (18) 0.16 148 (14) 378 (16) 0.11 
Values are number (%), mean ± SD, or median (interquartile range) unless otherwise stated. 
* Potential independent variables selected in the Cox proportional hazard models for all-cause death, cardiovascular death and a composite of aortic valve-
related death or hospitalization for heart failure.  
† Potential independent variables selected in the Cox proportional hazard models for aortic valve-related death, aortic valve-procedure death, sudden death, 
non-cardiovascular death and hospitalization for heart failure. 
‡ Body mass index was calculated as weight in kilograms divided by height in meters squared.
§ Anemia was defined by the World Health Organization criteria (hemoglobin <12.0 g/dl in women and <13.0 g/dl in men).
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Table S2. Baseline Characteristics of Patients in the Initial AVR Group: Dialysis versus Non-dialysis Patients 





Age, years 70.3±8.2 73.7±8.9 <0.001 
  Age ≥80 years*† 17 (13) 282 (27) <0.001 
Men* 87 (64) 420 (40) <0.001 
Body mass index‡ 20.8±3.1 22.5±3.6 <0.001 
  Body mass index <22* 95 (70) 527 (50) <0.001 
Body surface area, m2 1.49±0.18 1.50±0.18 0.56 
Any symptoms possibly related to aortic stenosis 103 (76) 802 (76) 0.84 
  Angina 33 (24) 258 (24) 0.97 
  Syncope 15 (11) 95 (9) 0.41 
  Heart failure 72 (53) 587 (55) 0.67 
Admission for heart failure at index echocardiography*† 28 (21) 242 (23) 0.59 
Hypertension* 97 (72) 710 (67) 0.24 
Current smoking* 12 (9) 71 (7) 0.34 
History of smoking 51 (38) 263 (25) 0.001 
Dyslipidemia 23 (17) 453 (43) <0.001 
On statin therapy 13 (10) 326 (31) <0.001 
Diabetes mellitus 32 (24) 244 (23) 0.85 
  On insulin therapy* 11 (8) 47 (4) 0.06 
Prior myocardial infarction* 11 (8) 40 (4) 0.02 
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Prior coronary artery bypass graft 10 (7) 22 (2) 0.002 
Prior open heart surgery 12 (9) 36 (3) 0.002 
Prior symptomatic stroke* 19 (14) 88 (8) 0.03 
Atrial fibrillation or flutter*† 29 (21) 178 (17) 0.17 
Aortic/peripheral vascular disease* 12 (9) 58 (5) 0.11 
Serum creatinine, mg/dl  0.8 (0.65-1.0)  
Anemia§* 121 (90) 508 (48) <0.001 
Liver cirrhosis (Child-Pugh B or C)* 2 (1) 4 (0.4) 0.14 
Malignancy 15 (11) 116 (11) 0.95 
  Malignancy currently under treatment*† 2 (1) 22 (2) 1.0 
Chest wall irradiation 1 (1) 6 (0.6) 0.57 
Immunosuppressive therapy 9 (7) 22 (2) 0.005 
Chronic lung disease 19 (14) 122 (11) 0.38 
  Chronic lung disease (moderate or severe)* 5 (4) 14 (1) 0.04 
Coronary artery disease* 76 (56) 322 (30) <0.001 
Logistic EuroSCORE, % 11.3 (7.1-18.9) 6.6 (4.2-10.6) <0.001 
EuroSCORE II, % 2.4 (1.8-4.1) 2.1 (1.3-3.5) 0.71 
STS-PROM score, % 7.3 (4.8-11.4) 2.5 (1.6-4.1) <0.001 
Etiology of aortic stenosis   <0.001 
  Degenerative 130 (96) 844 (79)  
  Congenital (Unicuspid, Bicuspid, Quadricuspid) 0 154 (15)  
  Rheumatic 4 (3) 49 (5)  
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  Others 0 10 (1)  
Echocardiographic variables    
Left ventricular end-diastolic diameter, mm 49.6±7.0 46.9±7.1 <0.001 
Left ventricular end-systolic diameter, mm  34.6±8.5 30.6±8.4 <0.001 
Left ventricular ejection fraction, %* 58.1±13.2 63.4±14.0 <0.001 
  Left ventricular ejection fraction <40% 16 (12) 87 (8) 0.15 
  Left ventricular ejection fraction <50% 32 (24) 173 (16) 0.03 
Interventricular septum thickness in diastole, mm 12.4±2.6 11.9±2.3 0.02 
Posterior wall thickness in diastole, mm 12.1±2.2 11.5±2.1 0.001 
Peak aortic jet velocity, m/s 4.41±0.82 4.74±0.82 <0.001 
Peak aortic jet velocity ≥5 m/s 33 (24) 396 (37) 0.003 
Peak aortic jet velocity ≥4 m/s*† 100 (74) 894 (84) 0.003 
Peak aortic pressure gradient, mmHg 80±29 93±32 <0.001 
Mean aortic pressure gradient, mmHg 49±18 54±20 0.005 
Aortic valve area (equation of continuity), cm2 0.69±0.16 0.64±0.17 0.009 
Aortic valve area index, cm2/m2 0.46±0.10 0.43±0.12 0.01 
Any combined valuvular disease (moderate or severe)*† 65 (48) 414 (39) 0.04 
Moderate or severe aortic regurgitation 35 (26) 259 (24) 0.70 
Moderate or severe mitral stenosis 8 (6) 43 (4) 0.31 
Moderate or severe mitral regurgitation 39 (29) 188 (18) 0.002 
Moderate or severe tricuspid regurgitation 21 (16) 126 (12) 0.22 
Tricuspid regurgitation pressure gradient ≥40 mmHg* 32 (24) 148 (14) 0.003 
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* Potential independent variables selected in the Cox proportional hazard models for all-cause death, cardiovascular death and a composite of aortic valve-
related death or hospitalization for heart failure.  
† Potential independent variables selected in the Cox proportional hazard models for aortic valve-related death, aortic valve-procedure death, non-
cardiovascular death and hospitalization for heart failure. 
‡ Body mass index was calculated as weight in kilograms divided by height in meters squared. 
§ Anemia was defined by the World Health Organization criteria (hemoglobin <12.0 g/dl in women and <13.0 g/dl in men). 
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Table S3. Baseline Characteristics in the Entire Cohort and in the Propensity-score Matched Cohort in Dialysis Patients: Initial AVR versus Conservative 
Groups 

















Age, years 70.3±8.2 74.7±8.4 <0.001 70.7±8.1 73.6±8.3 0.007 
  Age ≥80 years* 17 (13) 76 (28) <0.001 17 (15) 19 (17) 0.72 
Men* 87 (64) 155 (57) 0.17 72 (63) 72 (63) 1.0 
Body mass index† 20.8±3.1 20.3±3.9 0.24 20.7±3.1 21.0±2.8 0.45 
  Body mass index <22* 95 (70) 203 (75) 0.30 80 (70) 80 (70) 1.0 
Body surface area, m2 1.49±0.18 1.45±0.17 0.04 1.48±0.17 1.47±0.16 0.72 
Any symptoms possibly related to aortic stenosis* 103 (76) 95 (35) <0.001 82 (72) 85 (75) 0.65 
 Angina 33 (24) 27 (10) <0.001 26 (23) 14 (12) 0.04 
 Syncope 15 (11) 10 (4) 0.007 13 (11) 9 (8) 0.50 
 Heart failure 72 (53) 71 (26) <0.001 56 (49) 69 (61) 0.08 
Hypertension 97 (72) 190 (70) 0.76 82 (72) 82 (72) 1.0 
Current smoking 12 (9) 10 (4) 0.03 9 (8) 10 (9) 1.0 
History of smoking 51 (38) 69 (26) 0.01 44 (39) 52 (46) 0.28 
Dyslipidemia 23 (17) 55 (20) 0.42 20 (18) 21 (18) 0.86 
On statin therapy 13 (10) 32 (12) 0.50 11 (10) 12 (11) 0.83 
Diabetes mellitus 32 (24) 95 (35) 0.02 27 (24) 46 (40) 0.007 
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Prior myocardial infarction 11 (8) 37 (14) 0.10 11 (10) 8 (7) 0.63 
Prior percutaneous coronary intervention 26 (19) 71 (26) 0.12 25 (22) 22 (19) 0.62 
Prior coronary artery bypass graft 10 (7) 35 (13) 0.09 10 (9) 10 (9) 1.0 
Prior open heart surgery* 12 (9) 39 (14) 0.11 12 (11) 10 (9) 0.65 
Prior symptomatic stroke* 19 (14) 51(19) 0.23 17 (15) 13 (11) 0.43 
Atrial fibrillation or flutter 29 (21) 71 (26) 0.29 24 (21) 22 (19) 0.74 
Aortic/peripheral vascular disease 12 (9) 70 (26) <0.001 28 (25) 38 (33) 0.14 
Years from dialysis introduction   0.21   <0.001 
< 1 year 8 (6) 25 (9)  7 (6) 10 (9)  
  ≥ 1 year, < 5 years 33 (24) 83 (31)  25 (22) 63 (55)  
  ≥ 5 year, < 10 years 29 (21) 58 (21)  26 (23) 10 (9)  
  ≥ 10 years 65 (48) 104 (39)  56 (49) 31 (27)  
Anemia*‡ 121 (90) 214 (79) 0.009 100 (88) 102 (89) 0.68 
Liver cirrhosis (Child-Pugh B or C) * 2 (1) 4 (1) 1.0 1 (0.9) 0 1.0 
Malignancy 15 (11) 44 (16) 0.16 15 (13) 18 (16) 0.57 
  Malignancy currently under treatment* 2 (1) 11 (4) 0.23 2 (2) 2 (2) 1.0 
Chest wall irradiation* 1 (1) 1 (0.4) 1.0 1 (0.9) 0 1.0 
Immunosuppressive therapy* 9 (7) 8 (3) 0.08 7 (6) 4 (4) 0.54 
Chronic lung disease 19 (14) 21 (8) 0.045 16 (14) 13 (11) 0.55 
  Chronic lung disease (moderate or severe) * 5 (4) 6 (2) 0.52 4 (4) 5 (4) 1.0 
Logistic EuroSCORE, % 11.3 (7.1-18.9) 15.9 (8.8-25.1) <0.001 11.9 (7.4-20.0) 13.4 (7.9-23.2) 0.12 
EuroSCORE II, % 2.4 (1.8-4.1) 2.8 (2.0-4.9) <0.001 2.5 (1.8-4.3) 2.9 (2.4-4.7) 0.01 
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Etiology of aortic stenosis   0.05   0.20 
  Degenerative 130 (96) 264 (98)  112 (98) 110 (96)  
  Congenital (Unicuspid, Bicuspid, Quadricuspid) 0 4 (1)  0 3 (3)  
  Rheumatic 4 (3) 1 (0.4)  1 (0.9) 0  
  Infective endocarditis 1 (1) 0  1 (0.9) 0  
  Others 0 1 (0.4)  0 1 (0.9)  
Echocardiographic variables       
Left ventricular end-diastolic diameter, mm 49.6±7.0 48.6±7.4 0.20 49.4±7.1 51.8±7.3 0.02 
Left ventricular end-systolic diameter, mm  34.6±8.5 34.1±9.0 0.60 34.6±8.8 37.1±9.3 0.07 
Left ventricular ejection fraction, % 58.1±13.2 56.4±14.4 0.25 57.2±13.7 54.0±14.8 0.04 
  Left ventricular ejection fraction <40%* 16 (12) 41 (15) 0.36 16 (14) 23 (20) 0.22 
  Left ventricular ejection fraction <50% 32 (24) 73 (27) 0.47 29 (25) 37 (32) 0.24 
Interventricular septum thickness in diastole, mm 12.4±2.6 11.4±2.2 <0.001 12.2±2.6 11.3±2.4 0.004 
Posterior wall thickness in diastole, mm 12.1±2.2 11.0±1.8 <0.001 11.9±2.3 11.0±1.7 0.002 
Peak aortic jet velocity, m/s 4.41±0.82 3.74±0.80 <0.001 4.21±0.71 3.86±0.88 <0.001 
Peak aortic jet velocity ≥5m/s* 33 (24) 19 (7) <0.001 14 (12) 14 (12) 1.0 
Peak aortic jet velocity ≥4m/s 100 (74) 111 (41) <0.001 79 (69) 51 (45) <0.001 
Peak aortic pressure gradient, mmHg 80±29 59±25 <0.001 73.0±23.1 62.6±29.0 <0.001 
Mean aortic pressure gradient, mmHg 49±18 32±15 <0.001 43.0±14.0 32.3±15.0 <0.001 
Aortic valve area (equation of continuity), cm2 0.69±0.16 0.76±0.16 <0.001 0.70±0.15 0.77±0.14 <0.001 
Aortic valve area index, cm2/m2 0.46±0.10 0.53±0.12 <0.001 0.47±0.10 0.53±0.09 <0.001 
Any combined valvular disease (moderate or severe) * 65 (48) 101 (37) 0.04 52 (46) 56 (49) 0.60 
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Moderate or severe mitral stenosis 8 (6) 6 (2) 0.08 5 (4) 0 0.06 
Moderate or severe mitral regurgitation 39 (29) 63 (23) 0.22 32 (28) 37 (32) 0.47 
Moderate or severe tricuspid regurgitation 21 (16) 43 (16) 0.92 18 (16) 22 (19) 0.49 
Tricuspid regurgitation pressure gradient ≥40 mmHg 32 (24) 48 (18) 0.16 22 (19) 24 (21) 0.74 
Values are number (%), mean ± SD, or median (interquartile range) unless otherwise stated. 
* Potential independent variables relevant to the choice of initial AVR selected for logistic regression model to develop propensity-score for the choice of 
initial AVR. 
† Body mass index was calculated as weight in kilograms divided by height in meters squared. 
‡ Anemia was defined by the World Health Organization criteria (hemoglobin <12.0 g/dl in women and <13.0 g/dl in men). 
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Table S4. Baseline Characteristics in the Entire Cohort and in the Propensity-score Matched Cohort in Non-dialysis Patients: Initial AVR versus 
Conservative Groups 

















Age, years 73.7±8.9 80.3±9.4 <0.001 73.7±8.9 76.3±8.9 <0.001 
  Age ≥80 years* 282 (27) 1354 (58) <0.001 282 (27) 283 (27) 1.0 
Men* 420 (40) 781 (33) <0.001 420 (40) 417 (39) 0.93 
Body mass index† 22.5±3.6 21.7±3.9 <0.001 22.5±3.6 22.7±4.1 0.16 
  Body mass index <22* 527 (50) 1501 (64) <0.001 527 (50) 507 (48) 0.41 
Body surface area, m2 1.50±0.18 1.43±0.19 <0.001 1.50±0.18 1.49±0.21 0.12 
Any symptoms possibly related to aortic stenosis* 802 (76) 1005 (43) <0.001 802 (76) 809 (76) 0.75 
 Angina 258 (24) 180 (8) <0.001 258 (24) 173 (16) <0.001 
 Syncope 95 (9) 78 (3) <0.001 95 (9) 57 (5) 0.001 
 Heart failure 587 (55) 873 (37) <0.001 587 (55) 690 (65) <0.001 
Hypertension 710 (67) 1670 (71) 0.01 710 (67) 782 (74) <0.001 
Current smoking 71 (7) 103 (4) 0.005 71 (7) 91 (9) 0.10 
History of smoking 263 (25) 447 (19) <0.001 263 (25) 234 (22) 0.14 
Dyslipidemia 453 (43) 796 (34) <0.001 453 (43) 413 (39) 0.08 
On statin therapy 326 (31) 599 (26) 0.002 326 (31) 262 (25) 0.002 
Diabetes mellitus 244 (23) 526 (22) 0.71 244 (23) 228 (21) 0.40 
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Prior myocardial infarction 40 (4) 235 (10) <0.001 40 (4) 78 (7) <0.001 
Prior percutaneous coronary intervention 77 (7) 328 (14) <0.001 77 (7) 99 (9) 0.08 
Prior coronary artery bypass graft 22 (2) 132 (6) <0.001 22 (2.1) 19 (1.8) 0.64 
Prior open heart surgery* 36 (3) 229 (10) <0.001 36 (3) 31 (3) 0.53 
Prior symptomatic stroke* 88 (8) 345 (15) <0.001 88 (8) 89 (8) 0.94 
Atrial fibrillation or flutter 178 (17) 550 (23) <0.001 178 (17) 195 (18) 0.33 
Aortic/peripheral vascular disease 58 (5) 142 (6) 0.50 58 (5) 53 (5) 0.63 
Anemia*‡ 508 (48) 1274 (54) <0.001 508 (48) 508 (48) 1.0 
Liver cirrhosis (Child-Pugh B or C) * 4 (0.4) 28 (1) 0.02 4 (0.4) 2 (0.2) 0.69 
Malignancy 116 (11) 342 (15) 0.004 116 (11) 73 (7) 0.001 
  Malignancy currently under treatment* 22 (2) 114 (5) <0.001 22 (2) 12 (1) 0.08 
Chest wall irradiation* 6 (0.6) 17 (0.7) 0.60 6 (0.6) 0 0.03 
Immunosuppressive therapy* 22 (2) 92 (4) 0.006 22 (2) 20 (2) 0.76 
Chronic lung disease 122 (11) 238 (10) 0.23 122 (11) 116 (11) 0.68 
  Chronic lung disease (moderate or severe) * 14 (1) 87 (4) <0.001 14 (1) 10 (0.9) 0.41 
Logistic EuroSCORE, % 6.6 (4.2-10.6) 10.8 (6.6-18.3) <0.001 6.6 (4.2-10.6) 7.5 (4.8-12.8) <0.001 
EuroSCORE II, % 2.1 (1.3-3.5) 3.4 (2.0-5.5) <0.001 2.1 (1.3-3.5) 2.5 (1.4-4.1) <0.001 
STS-PROM score, % 2.5 (1.6-4.1) 3.9 (2.4-6.7) <0.001 2.5 (1.6-4.1) 2.9 (1.8-4.7) <0.001 
Etiology of aortic stenosis   <0.001   <0.001 
  Degenerative 844 (79) 2141 (91)  844 (79) 963 (91)  
  Congenital (Unicuspid, Bicuspid, Quadricuspid) 154 (15) 100 (4)  154 (15) 73 (7)  
  Rheumatic 49 (5) 96 (4)  49 (5) 20 (2)  
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  Others 10 (1) 10 (0.4)  10 (1) 6 (0.6)  
Echocardiographic variables       
Left ventricular end-diastolic diameter, mm 46.9±7.1 45.0±6.7 <0.001 46.9±7.1 46.4±7.2 0.17 
Left ventricular end-systolic diameter, mm  30.6±8.4 29.4±7.2 <0.001 30.6±8.4 30.1±7.7 0.23 
Left ventricular ejection fraction, % 63.4±14.0 63.5±12.9 0.72 63.4±14.0 63.9±12.3 0.87 
  Left ventricular ejection fraction <40%* 87 (8) 149 (6) 0.049 87 (8) 52 (5) 0.002 
  Left ventricular ejection fraction <50% 173 (16) 315 (13) 0.03 173 (16) 129 (12) 0.006 
Interventricular septum thickness in diastole, mm 11.9±2.3 11.0±2.2 <0.001 11.9±2.3 11.7±2.4 0.05 
Posterior wall thickness in diastole, mm 11.5±2.1 10.6±1.9 <0.001 11.5±2.1 11.2±2.1 0.01 
Peak aortic jet velocity, m/s 4.74±0.82 3.89±0.84 <0.001 4.74±0.82 4.36±1.00 <0.001 
Peak aortic jet velocity ≥5m/s* 396 (37) 250 (11) <0.001 396 (37) 370 (35) 0.24 
Peak aortic jet velocity ≥4m/s 894 (84) 1080 (46) <0.001 894 (84) 672 (63) <0.001 
Peak aortic pressure gradient, mmHg 93±32 63±28 <0.001 93±32 80±35 <0.001 
Mean aortic pressure gradient, mmHg 54±20 36±17 <0.001 54±20 46±22 <0.001 
Aortic valve area (equation of continuity), cm2 0.64±0.17 0.75±0.18 <0.001 0.64±0.17 0.73±0.20 <0.001 
Aortic valve area index, cm2/m2 0.43±0.12 0.53±0.13 <0.001 0.43±0.12 0.50±0.13 <0.001 
Any combined valvular disease (moderate or severe) * 414 (39) 978 (42) 0.14 414 (39) 419 (39) 0.82 
Moderate or severe aortic regurgitation 259 (24) 455 (19) 0.001 259 (24) 212 (20) 0.01 
Moderate or severe mitral stenosis 43 (4) 76 (3) 0.23 43 (4) 33 (3) 0.24 
Moderate or severe mitral regurgitation 188 (18) 473 (20) 0.09 188 (18) 224 (21) 0.048 
Moderate or severe tricuspid regurgitation 126 (12) 438 (19) <0.001 126 (12) 157 (15) 0.048 
Tricuspid regurgitation pressure gradient ≥40 mmHg 148 (14) 378 (16) 0.11 148 (14) 173 (16) 0.13 
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* Potential independent variables relevant to the choice of initial AVR selected for logistic regression model to develop propensity-score for the choice of 
initial AVR. 
† Body mass index was calculated as weight in kilograms divided by height in meters squared. 
‡ Anemia was defined by the World Health Organization criteria (hemoglobin <12.0 g/dl in women and <13.0 g/dl in men). 
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Table S5. Clinical Outcomes in the Propensity-score Matched Cohort in Dialysis Patients: Initial AVR versus Conservative Groups 
 
Initial AVR group  
Number of patients with at 




Conservative group  
Number of patients with at 







All-cause death 59 (37.0) 74 (66.6) 0.69 (0.49-0.98) 0.037 
Cardiovascular death 43 (50.5) 48 (50.0) 0.79 (0.52-1.20) 0.27 
Aortic valve-related death 24 (22.6) 25 (29.7) 0.87 (0.50-1.53) 0.63 
Aortic valve procedure-related death 23 (21.9) 2 (2.3) 10.60 (3.13-66.02) <0.001 
Sudden death 4 (12.9) 15 (18.8) 0.24 (0.07-0.65) 0.004 
Non-cardiovascular death 16 (25.2) 26 (33.2) 0.52 (0.27-0.96) 0.036 
Hospitalization for heart failure 10 (32.6) 13 (20.3) 0.61 (0.26-1.39) 0.24 
A composite of aortic valve-related 
death or hospitalization for heart 
failure 
33 (47.1) 30 (36.1) 0.95 (0.58-1.57) 0.85 
Number of patients with at least one event was counted through the entire follow-up period, while the cumulative incidence was truncated at 5-year. 
Follow-up was commenced on the day of the index echocardiography. 
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Table S6. Clinical Outcomes in the Propensity-score Matched Cohort in Non-dialysis Patients: Initial AVR versus Conservative Groups 
 
Initial AVR group  
Number of patients with at 




Conservative group  
Number of patients with at 







All-cause death 170 (18.7) 395 (35.8) 0.43 (0.36-0.52) <0.001 
Cardiovascular death 103 (11.3) 288 (27.6) 0.35 (0.28-0.44) <0.001 
Aortic valve-related death 41 (4.2) 219 (22.2) 0.19 (0.13-0.26) <0.001 
Aortic valve procedure-related death 24 (2.3) 17 (2) 1.35 (0.73-2.55) 0.35 
Sudden death 23 (3.0) 80 (6.6) 0.29 (0.18-0.46) <0.001 
Non-cardiovascular death 67 (8.3) 107 (11.4) 0.65 (0.47-0.87) 0.005 
Hospitalization for heart failure 87 (10.1) 274 (31.0) 0.28 (0.22-0.35) <0.001 
A composite of aortic valve-related 
death or hospitalization for heart 
failure 
129 (13.9) 375 (37.3) 0.31 (0.25-0.37) <0.001 
Number of patients with at least one event was counted through the entire follow-up period, while the cumulative incidence was truncated at 5-year. 
Follow-up was commenced on the day of the index echocardiography. 
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Table S7. Procedural Characteristics of AVR in the Initial AVR Group: Dialysis versus Non-dialysis Patients 





AVR with coronary artery bypass grafting 52 (40) 236 (23) <0.001 
AVR with any valve surgery 25 (19) 154 (15) 0.23 
AVR with mitral valve surgery 
   Mitral valve replacement 
   Mitral valve repair 
AVR with tricuspid valve surgery 
   Tricuspid valve replacement 
 Tricaupid valve repair 
AVR with replacement of ascending aorta 
AVR with annular dilatation 





 Bioprosthetic valve 
  18mm 
19mm 
  21mm 
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  24mm 
  25mm 
  27mm 
  29mm 
  Unknown 













  16mm 
  17mm 
  18mm 
  19mm 
  20mm 
  21mm 






















  23mm 9 (18) 26 (13)  
25mm 0 3 (1.5)  
27mm 0 3 (1.5)  
  29mm 0 2 (1)  
Unknown 1 (2) 3 (1.5)  
Values are number (%). 
In the initial AVR group, 1174 of 1197 patients actually underwent surgical AVR or TAVI. In the 1174 patients, TAVI was performed only in 11 non-dialysis 
patients, who were included in this Table. 
Regarding the prosthetic valve types, we did not have information in 20 patients who were operated on in hospitals other than the study participating centers. 
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Figure S1. Cumulative incidence of surgical AVR or TAVI in the conservative group: 
dialysis versus non-dialysis patients. 
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Figure S2. Propensity score-matched cohort in dialysis and non-dialysis patients for the 
sensitivity analysis. 
We used logistic regression model to develop propensity-score for the choice of initial 
AVR with 15 independent variables relevant to the choice of initial AVR listed in 
Supplementary Table 3. Patients in the conservative group were matched to those in the 
initial AVR group using a 1:1 greedy matching technique. 
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Figure S3. Cumulative incidence of all-cause death and sudden death in the propensity-score matched cohort in (A) dialysis patients and 
(B) non-dialysis patients: initial AVR versus conservative strategies. 
AVR=aortic valve replacement. 
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Figure S4. Cumulative incidences of (A) all-cause death and (B) hospitalization for heart 
failure after surgical AVR in the initial AVR group in dialysis patients: mechanical valve 
versus bioprosthetic valve. 
Follow-up was commenced on the day of surgical AVR. 
AVR=aortic valve replacement. 
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